German Metals and Mining Stock News

XTRA:NDA
XTRA:NDAMetals and Mining

Aurubis (XTRA:NDA) Valuation Check After Upgraded 2025–26 Earnings Guidance And Stronger Copper Trends

Why Aurubis stock is back on investors’ radar Aurubis (XTRA:NDA) has drawn fresh attention after raising its 2025–26 operating EBT guidance to €375 million to €475 million. This follows a first quarter with higher sales and net income versus a year earlier. See our latest analysis for Aurubis. The raised guidance and strong first quarter have coincided with a sharp move in the stock, with a 30.35% year to date share price return and a 102.07% total shareholder return over the past year...
XTRA:EVK
XTRA:EVKChemicals

Evaluating Evonik Industries (XTRA:EVK) Valuation After Annual Results And Dividend Confirmation

What the latest earnings and dividend mean for Evonik Industries (XTRA:EVK) Evonik Industries (XTRA:EVK) reported full year 2025 results with sales of €14,069 million and net income of €634 million, alongside confirming an annual dividend of €1.00 per share payable in June 2026. See our latest analysis for Evonik Industries. The release of full year 2025 results, which showed sales of €14.1b and net income of €634 million, appears to be in focus for investors. The 7 day share price return of...
XTRA:AT1
XTRA:AT1Real Estate

A Look At Aroundtown (XTRA:AT1) Valuation As New Bond Issuances Reshape Its Capital Structure

Why Aroundtown’s latest bond issuances matter for equity investors Aroundtown (XTRA:AT1) has been active in the debt markets recently, completing several transactions that reshape how it finances its real estate portfolio and manage upcoming obligations. On 30 January 2026, the company issued two senior unsecured bond series in Australia, each sized at A$300 million, with maturities of 5 and 10 years. Investor demand was strong, with the combined orderbook reportedly above A$1.9 billion, and...
XTRA:SRT3
XTRA:SRT3Life Sciences

Sartorius Q4 Margin Miss Shifts Focus To Earnings Quality And Mix

Sartorius (XTRA:SRT3) reported Q4 results that missed expectations, with pressure on margins. Management issued cautious guidance, highlighting a focus on margin recovery. The company plans to prioritize higher value product rollouts as part of its response. These updates signal a potential inflection point in how Sartorius balances growth, profitability, and product mix. Sartorius, a supplier of equipment and solutions for the biopharma and life sciences industry, operates within long term...